Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of BMS-986177 for prevention of recurrent ischemic stroke after acute ischemic stroke or TIA
MOH_2019-09-26_007415Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of milvexian in ischemic stroke and transient ischaemic attack (TIA) (9 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Not reported. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on MOH_2019-09-26_007415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-26_007415.